McKinsey January 9, 2025
Three lighthouse use cases serve as a blueprint for AI’s potential to improve the speed, efficiency, and quality of clinical trials.
Despite dedicated efforts across the biopharmaceutical industry to streamline clinical development, clinical trials remain complex, costly, and time-consuming. These challenges are compounded by an increasingly competitive and crowded trial landscape. Yet accelerating clinical development remains crucial—not just for patients but for the enterprise. A 12-month reduction in the clinical development timeline can add more than $400 million in net present value (NPV) across a sponsor’s portfolio while delivering immeasurable benefits to patients and their families.
Leading biopharma companies are addressing this challenge by adopting AI and machine learning (ML) to accelerate trials through scientific and operational improvements. Our analysis...
Today's Sponsors
Today's Sponsor